KURA Kura Oncology, Inc.

9.20
-0.20  -2%
Previous Close 9.40
Open 9.12
Price To book 3.20
Market Cap 177.99M
Shares 19,347,000
Volume 15,169
Short Ratio 3.77
Av. Daily Volume 64,467

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 first dosing announced January 17, 2016 with data due 1H 2018.
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 poster with data at European Hematology Association (EHA) conference on June 22-25, 2017. Exact date TBC.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 ongoing data released March 6, 2017. Poster at ASCO June 5, 2017. Abstract TPS2618.
Tipifarnib
HRAS mutant solid tumors - cancer
Phase 2 dosing commenced June 2016. Top-line data due 2H 2017.
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer